| TBX5, NuRD |
Congenital heart disease (Boogerd & Evans, 2016) |
| SREBP |
Treatment of cardiac metabolic diseases (Krycer et al., 2010) |
| VEGF |
Vascular disease (Danese, 2008b; Gianni-Barrera et al., 2014) |
| MyoD |
Heart disease (Kojima & Ieda, 2017) |
| PPAR γ
|
Obesity, diabetes and cardiovascular disease (Lee & Ge, 2014; Lehrke & Lazar, 2005) |
| PKCδ |
Thrombosis complications (Fischer, 2009) |
| SCL/TAL1 |
Anemia patient (Fujiwara, 2017) |
| Class IB phosphoinositide 3-kinase p110s |
Heart disease (Perino, Ghigo & Hirsch, 2010) |
| PI3K |
Heart failure (Weeks et al., 2012a) |
| SOX9 and myocardin |
Atherosclerosis, vascular calcification (Xu et al., 2012) |
| Klotho |
Cardiovascular diseases (Moe Sharon, 2012) |
| PITX2 |
Atrial fibrillation (AF) is the most common persistent Arrhythmia (Li, Dobrev & Wehrens, 2016) |
| FLYWCH1, PSORSIC3, G3BP1 |
Coronary artery disease (CAD) (Foroughi Asl et al., 2015
|
| Thyroid hormones (THs) |
Cardiovascular diseases (Rajagopalan & Gerdes, 2015) |
| CST |
Cardiovascular diseases (CVD) (Sushil, Malapaka & Nitish, 2018) |
| Etv2 |
Chronic vascular disease (Garry, 2016) |
